VAR2 Pharma’s co-authors have published new work on how the VAR2 Pharma rVAR2 proteins are internalized into tumor cells after binding to cell surface proteoglycans. The cell fate of rVAR2 proteins is important in the context of chondroitin sulfate targeting strategies, in particular our drug-delivery technology, currently in pre-clinical development phase.

Read more: https://www.nature.com/articles/s41598-022-07025-6